Here are 1-3 brief analogies for Electromed (ELMD):

• ResMed for airway clearance therapy.

• Dexcom for lung health.

• SmartVest Airway Clearance System: A line of products that apply high frequency chest wall oscillation (HFCWO) therapy for pulmonary care.
• SmartVest SQL System: Comprises an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose for delivering HFCWO therapy.
• SmartVest Connect: A wireless technology featuring a personalized HFCWO therapy management portal.
• Single Patient Use SmartVest and SmartVest Wrap products: Products designed for healthcare providers for use in acute care settings.

Electromed (ELMD) primarily sells its airway clearance therapy products to individuals. The company serves patients with various pulmonary conditions who require high-frequency chest wall oscillation (HFCWO) therapy. Its major customer categories are:

• Patients with Bronchiectasis
• Patients with Cystic Fibrosis
• Patients with Neuromuscular Disease

Jim Cunniff, President and Chief Executive Officer

Mr. Cunniff was appointed President and CEO of Electromed, effective July 1, 2023. He brings over 30 years of executive leadership experience in the MedTech and broader healthcare industry. Previously, he served as President, CEO, and Board Director for Leiters, Senior Vice President of Americas for Kinetics Concepts, and President of Emerging Markets for Stryker Corporation. Mr. Cunniff also served as President, Chief Executive Officer, and Board Director of Provista, a Vizient company, where he consistently grew revenue, executed two acquisitions, and shaped the strategic plan for the company.

Brad Nagel, Chief Financial Officer

Mr. Nagel has served as the Chief Financial Officer at Electromed since November 2022. He possesses over 15 years of financial leadership and strategic planning experience, including roles with Fortune 500 companies. Prior to joining Electromed, he was the Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic.

Christopher Holland, Chief Commercial Officer

Mr. Holland became the Chief Commercial Officer of Electromed in February 2022. He has 30 years of experience in driving commercial growth within Medical Technology markets. His previous roles include Vice President of Commercialization at Prosomnus Sleep Technologies, Inc., and Chief Commercial Officer and Executive Vice President of Sales and Global Business Development at Nonin Medical, Inc.

Kristine Owata, Vice President of Reimbursement & Payer Relations

Ms. Owata has been the Vice President of Reimbursement & Payer Relations at Electromed since October 2020. She has over 15 years of diverse leadership experience in areas such as people management, client experience, and process improvement. She previously served as president and director of Intelligere, Inc.

Peter Horwich, Vice President, Marketing

Mr. Horwich was appointed Vice President, Marketing in October 2024. He brings more than 20 years of MedTech expertise to Electromed, aiming to accelerate the adoption of SmartVest therapy and expand market reach.

Key Business Risks for Electromed (ELMD)

Electromed, Inc., a company specializing in high-frequency chest wall oscillation (HFCWO) therapy products, faces several key business risks inherent to the medical device industry and its specific market niche.

1. Intense Competition: The airway clearance therapy market is highly competitive and fragmented, with Electromed's SmartVest product competing against other established players such as Tactile Medical and Baxter. These competitors may possess stronger brand recognition, technological advantages, and higher growth rates, posing a continuous challenge to Electromed's market share and pricing power.
2. Reimbursement Policy Changes: Electromed's financial performance is significantly influenced by healthcare reimbursement policies. Changes to Medicare, Medicaid, or private insurance reimbursement policies, including coverage criteria and payment rates for HFCWO devices, could adversely affect the affordability and adoption of their products, thereby impacting revenue and profitability. The high cost of HFCWO devices can also be a barrier if not adequately reimbursed.
3. Efficacy and Alternative Therapies: The long-term demand for Electromed's HFCWO therapy could be impacted by evolving scientific evidence regarding its comparative efficacy against alternative airway clearance methods or by the discovery of new drugs and pharmaceutical treatments. While HFCWO has demonstrated efficacy for conditions like cystic fibrosis and bronchiectasis, ongoing research and the emergence of other effective therapies could shift treatment paradigms, potentially diminishing the perceived necessity or market for HFCWO devices.

Electromed, Inc. (ELMD) operates within the airway clearance therapy market, primarily offering High-Frequency Chest Wall Oscillation (HFCWO) systems like the SmartVest. The company targets patients with conditions such as bronchiectasis, cystic fibrosis, and neuromuscular disease.

The company itself estimates a potential total addressable market of $15.1 billion for its products in the U.S.. This figure is derived from an estimated 4.1 million patients multiplied by an assumed HFCWO average selling price of $10,500. Electromed also estimated the size of the U.S. homecare market for HFCWO to be approximately $265 million in 2025.

Here's a breakdown of the addressable markets for Electromed's main products and the diseases they serve:

High-Frequency Chest Wall Oscillation (HFCWO) Devices Market

• The global high-frequency chest-wall oscillation devices market size was valued at approximately USD 2.82 billion in 2024 and is projected to reach around USD 5.57 billion by 2034.
• Another estimate places the global market at $2.65 billion in 2025, expected to grow to $2.86 billion in 2026.
• The global airway clearance systems market, which includes HFCWO, was valued at USD 603.7 million in 2023 and is projected to grow to USD 976.4 million by 2032. North America accounted for a 32.5% share of the global airway clearance systems market in 2023. North America also held the largest share of the global high-frequency chest-wall oscillation devices market.

Bronchiectasis Market

• The global bronchiectasis market size was valued at USD 597.25 million in 2024 and is expected to reach USD 959.14 million by 2032.
• The 7 major bronchiectasis markets (7MM: United States, Germany, France, the United Kingdom, Italy, Spain, and Japan) reached a value of USD 459.4 million in 2024 and are expected to reach USD 766.7 million by 2035.
• In 2023, the total bronchiectasis market size in the 7MM was approximately USD 1,581.2 million, with the U.S. accounting for approximately USD 740.9 million (47% of the total 7MM market revenue).
• North America dominated the bronchiectasis market with the largest revenue share of 39.5% in 2024, and the U.S. bronchiectasis market captured 47.4% of that share within North America. The bronchiectasis therapeutic market in North America is expected to hold a 51% market share.
• The global bronchiectasis drugs market size was valued at USD 1.45 billion in 2025 and is projected to grow to USD 2.67 billion by 2034.

Cystic Fibrosis Market

• The global cystic fibrosis therapeutics market size was calculated at USD 11.81 billion in 2025, grew to USD 13.49 billion in 2026, and is projected to reach around USD 44.72 billion by 2035.
• Another report states the global cystic fibrosis market size stood at USD 5.12 billion in 2019 and is projected to reach USD 62.57 billion by 2032.
• The cystic fibrosis market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Canada) is forecast to grow from USD 11.1 billion in 2024 to USD 16.0 billion in 2034.
• In 2023, the cystic fibrosis market size in the 7MM was approximately USD 18,743 million, with the U.S. accounting for approximately USD 9,473 million.
• North America dominated the cystic fibrosis market with a 75.98% share in 2019. North America also dominated the cystic fibrosis therapeutics market in 2025.

Neuromuscular Disease Therapeutics Market

• The global neuromuscular disease therapeutics market size is forecast to increase by USD 13.73 billion, at a CAGR of 14.6% between 2024 and 2029.
• The neuromuscular disease therapeutics market reached US$ 11.89 billion in 2023, with a rise to US$ 13.70 billion in 2024, and is expected to reach US$ 45.62 billion by 2033.
• The neuromuscular disorders market size is expected to grow from $8.31 billion in 2025 to $8.98 billion in 2026. It is projected to grow to $12.07 billion in 2030.
• North America was the largest region in the neuromuscular disorders market in 2025. North America also dominated the market for neuromuscular disease therapeutics, accounting for a 44% growth during the forecast period (2024-2029).
• The nucleic acid and gene therapies in the neuromuscular disorders market are projected to grow from USD 9.4 billion in 2025 to USD 23.4 billion by 2035.

• Expanded Direct Sales Force and Enhanced Sales Productivity: Electromed is actively expanding its direct sales force, with plans to increase the number of representatives, and is focused on improving the productivity of these sales personnel. This strategy is anticipated to lead to incremental patient referrals and approvals, thereby boosting direct homecare revenue.
• Targeted "Triple Down on Bronchiectasis" Marketing Campaign: The company has launched a strategic marketing initiative aimed at increasing awareness among physicians and patients regarding the significant, underserved bronchiectasis market. This campaign, which promotes a "3-pronged treatment paradigm," is designed to capture a larger share of the nearly 800,000 diagnosed bronchiectasis patients who could benefit from the SmartVest system.
• Expansion of Payer Coverage: Electromed is continually working to secure new payer contracts, successfully adding millions of covered lives to its potential patient base. For instance, in the first half of fiscal year 2026, the company executed 25 new payer contracts, adding approximately 2.9 million covered lives, which broadens access to their airway clearance therapy products.
• Sustained Growth in Core Homecare and Distributor Channels: The company's core homecare business has demonstrated consistent strong performance, serving as a primary engine for revenue growth. Additionally, the distributor channel has shown robust growth, further extending the reach of Electromed's SmartVest system.
• Operational Efficiencies and Manufacturing Optimization: Electromed has implemented a manufacturing optimization plan and deployed a new CRM system. These operational enhancements are expected to improve overall efficiency, increase manufacturing capacity, and boost sales productivity, ultimately supporting scalable revenue growth and expanded operating leverage.

• Electromed's board of directors authorized a new share repurchase program of up to $10.0 million on September 9, 2025.
• During fiscal year 2025, Electromed repurchased $10.0 million of its common stock.
• In the six months ended December 31, 2025, approximately $3.8 million of shares were repurchased under the $10.0 million authorization.

• Electromed's issuance of stock for the three months and trailing twelve months ended December 2025 was $0.00 million.
• As of August 20, 2025, there were 8,349,176 shares of common stock outstanding.
• A director acquired 3,000 shares of restricted stock at $0 per share on December 1, 2025, as part of an insider stock award.

• Electromed invested $886,000 in capital expenditures in Q2 2026, marking an increase of 39.7% from the prior quarter.
• Capital expenditures in Q2 2026 totaled $0.63 million, representing a 172.1% increase year-over-year.
• Capital expenditures were reported as $252,000 in a quarter ending December 31, 2025.